161 related articles for article (PubMed ID: 17160431)
1. Improved survival in BRCA2 carriers with ovarian cancer.
Pal T; Permuth-Wey J; Kapoor R; Cantor A; Sutphen R
Fam Cancer; 2007; 6(1):113-9. PubMed ID: 17160431
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
3. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
5. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
[TBL] [Abstract][Full Text] [Related]
7. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
Lavie O; Chetrit A; Novikov I; Sadetzki S;
Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
[TBL] [Abstract][Full Text] [Related]
8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
9. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Bolton KL; Chenevix-Trench G; Goh C; Sadetzki S; Ramus SJ; Karlan BY; Lambrechts D; Despierre E; Barrowdale D; McGuffog L; Healey S; Easton DF; Sinilnikova O; Benítez J; García MJ; Neuhausen S; Gail MH; Hartge P; Peock S; Frost D; Evans DG; Eeles R; Godwin AK; Daly MB; Kwong A; Ma ES; Lázaro C; Blanco I; Montagna M; D'Andrea E; Nicoletto MO; Johnatty SE; Kjær SK; Jensen A; Høgdall E; Goode EL; Fridley BL; Loud JT; Greene MH; Mai PL; Chetrit A; Lubin F; Hirsh-Yechezkel G; Glendon G; Andrulis IL; Toland AE; Senter L; Gore ME; Gourley C; Michie CO; Song H; Tyrer J; Whittemore AS; McGuire V; Sieh W; Kristoffersson U; Olsson H; Borg Å; Levine DA; Steele L; Beattie MS; Chan S; Nussbaum RL; Moysich KB; Gross J; Cass I; Walsh C; Li AJ; Leuchter R; Gordon O; Garcia-Closas M; Gayther SA; Chanock SJ; Antoniou AC; Pharoah PD; ; ;
JAMA; 2012 Jan; 307(4):382-90. PubMed ID: 22274685
[TBL] [Abstract][Full Text] [Related]
10. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
11. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
12. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
14. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
16. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
McLaughlin JR; Rosen B; Moody J; Pal T; Fan I; Shaw PA; Risch HA; Sellers TA; Sun P; Narod SA
J Natl Cancer Inst; 2013 Jan; 105(2):141-8. PubMed ID: 23257159
[TBL] [Abstract][Full Text] [Related]
17. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
18. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers.
Evans DG; Gaarenstroom KN; Stirling D; Shenton A; Maehle L; Dørum A; Steel M; Lalloo F; Apold J; Porteous ME; Vasen HF; van Asperen CJ; Moller P
J Med Genet; 2009 Sep; 46(9):593-7. PubMed ID: 18413372
[TBL] [Abstract][Full Text] [Related]
19. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
[TBL] [Abstract][Full Text] [Related]
20. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
Rafnar T; Benediktsdottir KR; Eldon BJ; Gestsson T; Saemundsson H; Olafsson K; Salvarsdottir A; Steingrimsson E; Thorlacius S
Eur J Cancer; 2004 Dec; 40(18):2788-93. PubMed ID: 15571962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]